Key result
Intravesical BCG instillation given 2 years prior caused a 2.5-cm infrarenal mycotic aortic pseudoaneurysm that developed acutely within 2 weeks of a normal CT scan.
Why the study?
Mycotic aortic aneurysm caused by Mycobacterium is a rare, late, systemic, and serious complication of intravesical Bacillus Calmette-Guérin instillation for bladder cancer.
Case Report (n=1)
No
Clinicians should maintain a high index of suspicion for mycotic aortic aneurysm in patients with prior intravesical BCG therapy presenting with abdominal pain, as pseudoaneurysms can develop acutely within 2 weeks and require targeted anti-mycobacterial therapy alongside endovascular stenting.
Answers are grounded in this paper and cite their sources.
Raises awareness of rapid mycotic aneurysm post-BCG; single case leaves open incidence, screening, and management.
Background: Mycotic Aortic aneurysms (MAA) are saccular aneurysms of the infected aortic wall. Mycobacterium, compared with other bacteria, is less likely to cause MAA; most cases follow, but it is a rare, late, systemic, and serious complication of intravesical Bacillus Calmette-Guérin (BCG) instillation for bladder cancer. Case Presentation: A 65-year-old male with a history of hypertension, hyperlipidemia, diabetes mellitus, diabetic foot ulcer with methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia, status post partial toe amputation, and papillary urothelial carcinoma treated with transurethral resection and intravesical BCG instillation, recently underwent a computed tomography (CT) abdomen 2 weeks ago for abdominal pain, which revealed colonic stool without other pathological findings, who currently presented with worsening abdominal pain, and the CT scan identified a new 2.5-centimeter pseudoaneurysm of the infrarenal aorta, associated with a periaortic and aortocaval mass, likely a hematoma, infectious mycotic aneurysm, or neoplastic process. The patient received intravenous piperacillin-tazobactam for presumed MSSA, a potential cause of a mycotic aneurysm, which was later discontinued after negative blood cultures. Vascular surgery consultation led to endovascular aortic stenting. Infectious disease recommended a Karius test; despite no warning signs, it returned positive for the Mycobacterium tuberculosis complex, and a diagnosis of a BCG-induced aneurysm was made. The patient was treated with isoniazid, rifampin, ethambutol, and pyridoxine, then continued isoniazid and rifampin for 9 months. Conclusion: We presented a rare case of a BCG-induced mycotic aortic aneurysm that developed within 2 weeks. Therefore, we need a low threshold for MAA in patients with a history of intravesical BCG instillations who present with worsening abdominal pain, even if prior imaging 2 weeks ago showed no warning signs and instillations were given 2 years ago. Testing and diagnosing a BCG-induced aneurysm are necessary despite endovascular intervention, because it can further infect the stent and form an abscess if untreated.
No takes yet. Share an insight, caveat, or question.
Parsi et al. (2026) conducted a case report in Bacillus Calmette-Guérin (BCG)-induced mycotic infrarenal aortic pseudoaneurysm (n=1). Endovascular aortic stenting and anti-mycobacterial therapy (isoniazid, rifampin, ethambutol, pyridoxine) was evaluated on Diagnosis and resolution of BCG-induced mycotic aortic aneurysm. Intravesical BCG instillation given 2 years prior caused a 2.5-cm infrarenal mycotic aortic pseudoaneurysm that developed acutely within 2 weeks of a normal CT scan.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: